title: Attack the tumor counterattack-c-FLIP expression in Jurkat-T-cells protects against apoptosis induced by coculture with SW620 colorectal adenocarcinoma cells.
abstract: BACKGROUND
  Cancer development relies on a variety of mechanisms that facilitate tumor growth despite the presence of a functioning immune system, employing different mechanisms to escape immune rejection. Tumors may eliminate tumor-infiltrating lymphocytes and suppress anti-tumor immune responses, a process called "tumor counterattack," based on activation-induced cell death via the FAS/FAS-ligand system. To overcome this tumor-cell survival strategy, we examined the hypothesis that the sensitivity of FAS mediated apoptosis of Jurkat-T-cells can be suppressed by FLIP transfection of Jurkat-T-cells.
  
  
  METHODS
  Jurkat-T-cells were transfected with the FLICE-inhibitory protein FLIP in order to bestow them with a resistance to FAS-receptor-mediated apoptosis. FLIP-transfected and non-transfected Jurkat-T-cells were grown in coincubation with SW620 cells and the rates of apoptosis measured via FACS-analysis of Annexin-V.
  
  
  RESULTS
  First, the tumor-counterattack described in the literature was confirmed. About 20% of Jurkat-T-Cells underwent apoptosis in coculture with SW620 cells. After coincubation of SW620 cells with FLIP transfected Jurkat-T-cells the apoptotic rate was significant reduced at levels below 4%.
  
  
  CONCLUSIONS
  Transfection of Jurkat-T-cells with FLIP reduces the sensitivity of Jurkat-T-cells to FAS-mediated apoptosis and may lead to an improved capability to antagonize the inherent tumor survival strategy of SW620 cells.
authors.affiliation: Department of Plastic, Hand, and Reconstructive Surgery, Sarcoma Center Saxony, Germany. steiert.andreas@mh-hannover.de
authors.forename: Andreas E
authors.initials: AE
authors.lastname: Steiert
authors.forename: Daniel
authors.initials: D
authors.lastname: Sendler
authors.forename: Willam F
authors.initials: WF
authors.lastname: Burke
authors.forename: Claudia Y
authors.initials: CY
authors.lastname: Choi
authors.forename: Kerstin
authors.initials: K
authors.lastname: Reimers
authors.forename: Peter M
authors.initials: PM
authors.lastname: Vogt
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology*; D017209:Apoptosis / Q000502:physiology*; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000235:genetics / Q000378:metabolism*; D002450:Cell Communication / Q000502:physiology; D064987:Cell- and Tissue-Based Therapy; D018920:Coculture Techniques; D015179:Colorectal Neoplasms / Q000276:immunology / Q000473:pathology*; D053222:Fas Ligand Protein / Q000378:metabolism; D005786:Gene Expression Regulation / Q000502:physiology*; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology*; D019169:Jurkat Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D008875:Middle Aged; D014162:Transfection; D019014:fas Receptor / Q000378:metabolism
chemical_list: D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; C506386:CFLAR protein, human; D053222:Fas Ligand Protein; D019014:fas Receptor